Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Placebo-controlled, Randomized Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve

NCT00225290 is registered in ClinicalTrials.gov with TTY Biopharm as lead sponsor.

NCT NCT00225290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00225290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Placebo-controlled, Randomized Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
Lead sponsor
TTY Biopharm
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2003
Completion date
Not reported
Enrollment
230 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular